Hepatocellular carcinoma is frequently driven by several signaling networks operating at the same time. Among the most important are the mechanistic target of rapamycin, or mTOR, pathway and the extracellular signal-regulated kinase, or ERK, pathway. These systems help cancer cells grow, divide, produce proteins and adapt to metabolic stress. Their activity can also suppress ferroptosis, allowing malignant cells to survive the oxidative damage associated with rapid growth and anticancer treatment.

The new study focused on 4EBP1, a protein that regulates the initiation of protein synthesis downstream of mTOR. When 4EBP1 is phosphorylated, its ability to restrain translation is weakened, helping cells maintain the high level of protein production required for tumor expansion. The investigators examined whether altering 4EBP1 could change the response of β-catenin-mutant hepatocellular carcinoma cells to rapamycin and other targeted drugs.

Experiments were performed in MHCC97H and SNU449 liver cancer cells engineered to express either the normal form of 4EBP1, a modified form known as 4EBP1A4, or additional HSP90β. The cells were then exposed to rapamycin, an mTOR inhibitor, and analyzed for changes in signaling, oxidative stress and ferroptosis. The researchers used Western blotting, co-immunoprecipitation and immunofluorescence to track protein interactions and determine how 4EBP1 influences the machinery that controls cellular antioxidant defenses.

The results showed that rapamycin inhibited mTOR signaling unevenly. It more effectively reduced phosphorylation of the ribosomal protein S6, a marker of mTORC1 activity, than it reduced phosphorylation of 4EBP1. At the same time, rapamycin promoted ferroptosis, suggesting that cancer cells may respond to mTOR inhibition not only through reduced growth signaling but also through increased vulnerability to iron-dependent oxidative injury. Introducing 4EBP1A4 intensified this effect and made rapamycin more effective at suppressing tumor-cell proliferation.

The researchers identified a mechanism involving HSP90β, a molecular chaperone that helps stabilize other proteins, and Keap1, a regulator of the antioxidant transcription factor Nrf2. Under normal conditions, Keap1 binds Nrf2 and directs it toward ubiquitination and degradation. When Nrf2 is stabilized, it activates genes that protect cells from oxidative stress, including genes involved in glutathione production and detoxification. This antioxidant program can make cancer cells more resistant to ferroptosis.

According to the study, 4EBP1A4 competes with Keap1 for binding to HSP90β. This interaction displaces Keap1 from HSP90β and favors the formation of Keap1–Nrf2 complexes. As a result, Nrf2 undergoes increased ubiquitination and degradation, weakening the cancer cell’s antioxidant defenses. With less Nrf2 available to control protective genes, lipid peroxides accumulate in the cell membranes, pushing tumor cells toward ferroptotic death. The findings place 4EBP1 at the center of a signaling connection between protein synthesis, molecular chaperones and redox control.

The study also tested a broader drug strategy designed to block compensatory signaling. In addition to rapamycin, the researchers examined MLN0128, an inhibitor capable of targeting both mTORC1 and mTORC2, and PD901, an inhibitor of the ERK pathway. Each treatment reduced phosphorylated 4EBP1, induced markers of ferroptosis and inhibited the growth of hepatocellular carcinoma cells. However, the combination of MLN0128 and PD901 produced the strongest effects in cell-based experiments, indicating that simultaneous inhibition of mTOR and ERK may prevent the signaling escape routes that often limit targeted therapies.

The combination was also evaluated in mouse models of liver cancer generated through hydrodynamic tail vein injection of plasmids carrying c-Met and a truncated, constitutively active form of β-catenin. A second model additionally expressed 4EBP1A4. In these animals, the treatment regimens were assessed for their ability to slow tumor progression. The dual MLN0128–PD901 treatment showed superior antitumor activity, while the presence of 4EBP1A4 further supported ferroptosis and improved treatment sensitivity. These findings suggest that disrupting both mTOR and ERK signaling could be particularly relevant for tumors driven by aberrant β-catenin activity.

The researchers conclude that mTORC1, mTORC2 and ERK signaling promote β-catenin-mutant hepatocellular carcinoma partly by increasing 4EBP1 phosphorylation and suppressing ferroptosis. Restoring the ferroptosis-promoting activity of 4EBP1, or pharmacologically targeting the pathways that regulate it, may therefore offer a new way to overcome resistance to mTOR inhibitors. Although the results remain preclinical and require validation in human studies, the 4EBP1/HSP90β/Nrf2 pathway provides a potential framework for developing combination treatments that attack tumor growth and antioxidant protection at the same time.

Subject of Research:
β-catenin-mutant hepatocellular carcinoma, mTOR and ERK signaling, 4EBP1/HSP90β/Nrf2 regulation, ferroptosis, and combination cancer therapy.

Article Title:
Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction

News Publication Date:
16-Jun-2026

Web References:
Journal of Clinical and Translational Hepatology: https://www.xiahepublishing.com/journal/jcth
DOI: https://doi.org/10.14218/JCTH.2026.00072

References:
Xu M, Shang R, et al. “Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction.” Journal of Clinical and Translational Hepatology. DOI: 10.14218/JCTH.2026.00072

Image Credits:
Meng Xu, Runze Shang

Keywords:
Hepatocellular carcinoma; β-catenin; mTOR inhibitors; ferroptosis; 4EBP1; HSP90β; Nrf2; Keap1; ERK signaling; combination therapy; liver cancer.

CoQ10, a lipophilic molecule embedded within the inner mitochondrial membrane, functions fundamentally as an electron carrier in the mitochondrial respiratory chain. However, emerging evidence positions CoQ10 oxidoreductases as critical modulators of redox balance, influencing a cell’s propensity to undergo ferroptosis. Ferroptosis is characterized by iron-driven accumulation of lipid-based reactive oxygen species (ROS), disrupting cellular membranes and leading to an oxidative demise distinct from apoptosis or necrosis. This pathway has garnered attention for its potential to selectively target cancer cells resistant to conventional apoptosis-inducing therapies.

The research team deciphers how CoQ10 oxidoreductases exert a finely-tuned redox regulation, effectively governing ferroptotic sensitivity. These enzymes catalyze the reduction of CoQ10, sustaining its antioxidant capacity to mitigate lipid peroxidation. Intriguingly, certain cancers exhibit dysregulated expression or activity of these oxidoreductases, skewing the redox balance and fostering resistance against ferroptotic triggers. This mechanistic insight deepens our understanding of how cancer cells adapt to oxidative stress, potentially exploiting CoQ10 pathways to evade death.

A central revelation from the study is how CoQ10 oxidoreductase activity functions not only as a metabolic safeguard but also as a regulatory nexus controlling lipid peroxide detoxification. By reducing CoQ10, these enzymes replenish ubiquinol pools—powerful chain-breaking antioxidants that inhibit the propagation of lipid radicals in membranes. This antioxidative shield forms a biochemical barrier against ferroptotic induction, supporting cancer cell survival amid fluctuating oxidative milieus.

Ferroptosis has emerged as a compelling alternative to traditional apoptosis-centered therapies, particularly in malignancies exhibiting refractory resistance or mutated apoptotic machinery. The modulation of CoQ10 oxidoreductases, therefore, uncovers a therapeutic opportunity to sensitize tumors to ferroptotic death. Pharmacological inhibition or genetic suppression of these enzymes could dismantle the antioxidative defenses, augmenting lipid peroxidation and tipping the scales toward ferroptosis. Such strategies may offer a precision oncology approach, exploiting metabolic vulnerabilities while sparing normal tissues.

Adding complexity, the study highlights the context-dependent roles of different CoQ10 oxidoreductases isoforms across various cancer types. Some enzymes are upregulated, conferring enhanced ferroptosis resistance, whereas others might paradoxically promote oxidative stress under specific metabolic states. This heterogeneity accentuates the necessity for tailored therapeutic designs considering tumor-specific redox landscapes and CoQ10 enzymatic profiles.

Moreover, the researchers explore the cross-talk between CoQ10 oxidoreductases and other ferroptosis regulators, such as glutathione peroxidase 4 (GPX4) and membrane lipid remodeling enzymes. Inhibitory effects on CoQ10 oxidoreductases synergize with GPX4-targeting agents, generating combinatorial lethality that dismantles both lipid peroxide scavenging and detoxification pathways. This dual targeting could overcome resistance mechanisms and potentiate ferroptotic responses in challenging cancer subtypes.

Beyond its anti-ferroptotic functions, CoQ10 reduction by these oxidoreductases indirectly influences mitochondrial bioenergetics and ROS generation, highlighting an intricate feedback loop intertwining metabolic flux and redox signaling. As cancer cells often rewire mitochondrial dynamics to fuel aggressive phenotypes, manipulating CoQ10 oxidoreductase activity could disrupt cellular energetics, further sensitizing tumors to ferroptotic death.

The therapeutic implications of these findings are manifold. Small molecules modulating CoQ10 oxidoreductase activity offer a promising class of anticancer agents. Currently, several inhibitors are in preclinical evaluation, aiming to destabilize ubiquinol regeneration and collapse cellular redox defenses. Nanotechnology-enhanced delivery systems engineered to target tumors could also enhance drug specificity, reducing off-target effects and oxidative toxicity to healthy tissues.

Translationally, the elucidation of CoQ10 oxidoreductases as ferroptosis gatekeepers may provide prognostic biomarkers for patient stratification. Expression levels or enzymatic activity profiles could predict tumor susceptibility to ferroptosis-inducing therapies, enabling more personalized treatment regimens. Additionally, monitoring redox metabolites derived from CoQ10 pathways may serve as dynamic markers of therapeutic response.

Despite these advances, challenges remain in fully deciphering the intricate regulation of ferroptosis by CoQ10 oxidoreductases. Tumor microenvironment factors such as hypoxia, nutrient availability, and iron metabolism intricately modulate ferroptotic outcomes and CoQ10 enzyme function. Future studies must integrate multi-omic and spatial profiling to map these interactions comprehensively, paving the way for sophisticated intervention strategies.

In conclusion, the pioneering work of Lee and colleagues spotlights CoQ10 oxidoreductases as critical arbiters of ferroptotic cell death in cancer, functioning through redox regulation of lipid peroxide detoxification and cellular bioenergetics. Their dual role in shielding tumor cells and offering a therapeutic Achilles’ heel heralds a new chapter in redox biology and cancer therapy. As ferroptosis-based interventions advance toward clinical reality, targeting CoQ10 oxidoreductases emerges as a promising strategy to overcome drug resistance and improve patient outcomes in the relentless battle against cancer.

The implications of these findings extend beyond oncology, potentially informing therapeutic approaches for other diseases characterized by dysregulated redox homeostasis and lipid peroxidation, including neurodegeneration and cardiovascular disorders. The nuanced understanding of CoQ10 oxidoreductase function thus heralds broader biomedical significance, representing a cornerstone of future redox medicine.

Subject of Research:
CoQ10 oxidoreductases in ferroptosis regulation and cancer therapy

Article Title:
CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities.

Article References:
Lee, J., Yoo, I., Kim, M. et al. CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01736-w

Image Credits: AI Generated

DOI: 03 June 2026